Dr. Steven C. Cramer Presents Stem Cell Therapeutics Corp.'s Final Phase IIa BETAS Safety Trial Results
20 February 2009 - 1:44AM
Marketwired
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) is pleased to
announce a presentation of the complete positive results of the
Phase IIa BETAS trial conducted by Drs. Steven Cramer, Michael Hill
and David Brown at the International Stroke Conference, February
19, 2009 in San Diego, CA.
The poster presentation is entitled "Safety of Beta-hCG and EPO
in Acute Ischemic Stroke" and is a comprehensive evaluation of the
safety and efficacy results of the completed Phase IIa BETAS
trial.
Analysis of this trial by Dr. Steven C. Cramer, the Principle
Investigator, highlights three key conclusions:
1. No Safety Concerns were present: NTx(TM)-265 administered to
12 patients with Acute Ischemic Stroke showed no Serious Adverse
Events related to treatment.
2. ALL 12 patients enrolled in the trial and completing day 90
review improved; each recovered at least 4 points on the National
Institute of Health Stroke Scale (NIHSS) and, on average, patient
improved was greater than 6 points.
3. The 9 day treatment of beta-human Chorionic Gonadotropin
(b-hCG) followed by Erythropoietin (EPO), started within 48 hours
of stroke onset, and directly translated from a preclinical
protocol, is safe. This therapy had minimal hematological effects,
and was associated with significant clinical gains.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a Canadian public biotechnology company (TSX VENTURE: SSS)
focused on the development and commercialization of drug-based
therapies to treat central nervous system diseases. SCT is a leader
in the development of therapies that utilize drugs to stimulate a
patient's own resident stem cells. The Company's programs aim to
repair neurological function lost due to disease or injury. SCT's
extensive patent portfolio of owned and licensed intellectual
property supports the potential expansion into future clinical
programs in numerous neurological diseases such as traumatic brain
injury, multiple sclerosis, Huntington's disease, Alzheimer's
disease, and ALS.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President
and CEO (403) 245-5495 ext.224 Email: amoore@stemcellthera.com Stem
Cell Therapeutics Corp. Chloe Douglas-Crampton Investor Relations
(403) 245-5495 ext. 221 Email: crampton@stemcellthera.com Website:
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Aug 2024 to Oct 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Oct 2023 to Oct 2024